Home
About Us
    About YolTech
    Leadership
    Advisory Board
    Investors
Science
    Genome Editing Platform
    LNP Delivery Platform
Pipeline
    Pipeline
        Metabolic Disease
        Genetic Disease
        Infectious Disease
    Disease
        Familial Hypercholesterolemia (FH)
        Hereditary Transthyretin Amyloidosis (ATTR)
        Atherosclerotic Cardiovascular Disease (ASCVD)
        Primary Hyperoxaluria (PH1)
        Hereditary Angioedema (HAE)
        Hepatitis B
News
    Press Release
        YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
        Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
        YolTech Gains Patent for Advanced Base Editing Technology
        YolTech Announces Appointment of Tony W.Ho as Scientific Advisor
        First Patient Dosed in Clinical Trial of YOLT-201 for ATTR-CM
        YolTech’s Founder Interviewed by UCB China Voice Journal
        YolTech Announces NMPA Acceptance of IND Application for YOLT-201 to Treat hATTR
        YolTech Secured $15 Million in Series A+ Financing
    Media Release
        CDE Clears IND Application for Therapeutic Candidate Targeting ATTR
        YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
        Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
        Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
        YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024
        First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
    Publication
Career
    Corporate Culture
    Job Opportunites
Contact Us
    contact